333 related articles for article (PubMed ID: 24285872)
1. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.
Hakimi AA; Furberg H; Zabor EC; Jacobsen A; Schultz N; Ciriello G; Mikklineni N; Fiegoli B; Kim PH; Voss MH; Shen H; Laird PW; Sander C; Reuter VE; Motzer RJ; Hsieh JJ; Russo P
J Natl Cancer Inst; 2013 Dec; 105(24):1862-70. PubMed ID: 24285872
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
4. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of body mass index in Korean patients with renal cell carcinoma.
Jeon HG; Jeong IG; Lee JH; Lee CJ; Kwak C; Kim HH; Lee SE; Lee E
J Urol; 2010 Feb; 183(2):448-54. PubMed ID: 20006879
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
[TBL] [Abstract][Full Text] [Related]
8. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry.
Saitta C; Afari JA; Walia A; Patil D; Tanaka H; Hakimi K; Wang L; Meagher MF; Liu F; Nguyen MV; Puri D; Cerrato C; Saidian A; Kobayashi M; Fukuda S; Fujii Y; Master V; Derweesh IH
Urol Oncol; 2024 Apr; 42(4):119.e1-119.e16. PubMed ID: 38341362
[TBL] [Abstract][Full Text] [Related]
11. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
Parker AS; Lohse CM; Cheville JC; Thiel DD; Leibovich BC; Blute ML
Urology; 2006 Oct; 68(4):741-6. PubMed ID: 17070345
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.
Kamat AM; Shock RP; Naya Y; Rosser CJ; Slaton JW; Pisters LL
Urology; 2004 Jan; 63(1):46-50. PubMed ID: 14751346
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma.
Yuan Y; Yang X; Li Y; Liu Q; Wu F; Qu H; Gao H; Ge J; Xu Y; Wang H; Wang Y; Zhao Z
Pathol Res Pract; 2020 Nov; 216(11):153227. PubMed ID: 33027752
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
15. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap.
Shi B; Ding J; Qi J; Gu Z
Int J Med Sci; 2021; 18(9):2063-2075. PubMed ID: 33850477
[TBL] [Abstract][Full Text] [Related]
17. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
18. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.
Donin NM; Pantuck A; Klöpfer P; Bevan P; Fall B; Said J; Belldegrun AS; Chamie K
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1326-32. PubMed ID: 27418270
[TBL] [Abstract][Full Text] [Related]
19. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]